According to the World Health Organization (WHO), in 2020, there are approximately 37 million people living with HIV (PLWH) worldwide with an additional 1.5 million newly diagnosed individuals each year. In the United States, 1.2 million people live with HIV, and 35,000 new infections occur annually. Despite the Department of Health and Human Services (HHS) recommendation that all PLWH begin antiretroviral therapy (ART), only 35% of PLWH in this country receive HIV-related medical care, of whom 56.8% are virally suppressed. The HHS HIV treatment guidelines for adolescents and adults living with HIV was last updated in January 2022, and it divides the recommended ART regimens into 2 categories:
- recommended initial regimens for most people with HIV (RIR-MPH)
- recommended initial regimens in certain clinical situations (RIR-CCS).
The differences between the 2 categories are that the RIR-CCS have some disadvantages over the RIR-MPH, including increased incidence and severity of adverse drug reactions (ADRs), need for more baseline testing and ongoing monitoring, less supporting data for use obtained from randomized clinical trials, increased risk for drug–drug interactions (DDIs), and lower barrier to HIV resistance. The guidelines also introduce the option to start PLWH on ART at their first HIV-related medical visit or soon after, usually within days to weeks of HIV diagnosis (termed immediate start and rapid start, respectively).
Read the full review at Infectious Disease Special Edition.
Source : Infectious Disease Special Edition
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.